HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Prop 65 Aloe Vera Listing Update; Beautycounter Sales Soar; More

This article was originally published in The Rose Sheet

Executive Summary

Comments are now being accepted through June 9 on California's proposal to add Aloe vera whole leaf extract to the Prop 65 substances list. More news in brief.

You may also be interested in...

Beautycounter On 'National Radar' With Regulatory Reform Mission

Upping its bid to disrupt the cosmetics market, Beautycounter hosted a congressional briefing Nov. 17 to advocate stronger industry oversight, putting its weight behind the Personal Care Products Safety Act in particular. The direct seller, which has self-banned 1,500 ingredients from its offerings, has seen its sales and following grow rapidly since launching less than three years ago and aligning itself with leading NGOs.

Supreme Court May Hear Cosmetics Case Exploring Federal Preemption

The United States Solicitor General is expected to file a brief early in 2015 on a case examining if the Federal Food, Drug and Cosmetic Act preempts an unfair competition claim in California pertaining to the cosmetics/drugs regulatory divide. The case, Athena Cosmetics vs. Allergan, could be heard by the Supreme Court and bring attention to the way cosmetics are defined and regulated under federal law.

Molnupiravir To Reach 105 LMICs Through MPP Agreement

Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts